No abstract available.
Peripheral Arterial Disease*

No abstract available.
Adult* ; Humans ; Prevalence*

No abstract available.
Diabetes Mellitus, Type 2*

No abstract available.
Thyroiditis, Autoimmune*

No abstract available.
Metabolism*

No abstract available.
Base Sequence* ; DNA* ; Internet* ; Sequence Analysis, DNA*

No abstract available.
Meningitis, Aseptic*

No abstract available.
Electric Stimulation* ; Pelvic Floor*

BACKGROUND: Tego-51(R), one of the amphoteric surfactants, has been considered as an effective disinfectant having both bactericidal and fungicidal effect. The author evaluated inactivation effect of Tego-51(R) on viruses causing disease in humans. METHODS: Influenza virus B, respiratory syncytial virus (RSV), herpes simplex virus 1 (HSV-1), adenovirus and echovirus 30 were exposed to diluted Tego-51(R) solution (1% and 0.1%) for 5, 10 and 30 minutes respectively and were inoculated onto the following cells: Influenza virus B, MDCK; RSV, HEp-2; HSV-1, HEp-2; adenovirus, Vero; and echovirus 30, RD. After incubation for 5 to 6 days, viral infection was identified with indirect immunofluorescent methods. RESULTS: Influenza virus B, RSV and HSV-1 which are enveloped viruses were inactivated after exposure of the viruses to Tego-51(R) for 5 minutes. Non-enveloped adenovirus and echovirus 30 were not inactivated after exposure for 30 minutes. CONCLUSIONS: Tego-51(R) appears to be effective in inactivation of enveloped viruses at concentrations used for disinfection of pathogenic bacteria and fungi.
Adenoviridae ; Bacteria ; Disinfection ; Enterovirus B, Human ; Fungi ; Herpesvirus 1, Human ; Humans ; Orthomyxoviridae ; Respiratory Syncytial Viruses ; Surface-Active Agents ; Virus Inactivation*

No abstract available.